mardi 22 mars 2016

Onco Actu du 22 mars 2016

4.12 Biopsies liquides

Inside the race to diagnose cancer from a simple blood draw [STAT]

4.9 Dép., diag. & prono. - Sein

Doctors often disagree on when to call abnormal breast cells cancer [Reuters]

5. Traitements

Nanoparticle-Based Cancer Therapies Shown to Work in Humans [Caltech]

5.12.2 Immunothérapies - CAR-T

CAR-T Startup Gets €51M from Top and New Investors [Labiotech]

5.2.3 Pharma - économie

Collaboration to develop cancer therapeutics [Harvard Gazette]

Merck's $20M-plus Harvard deal offers a lesson on the new Economics 101 of preclinical R&D [FierceBiotech]

Tech Megatransfer: Merck Pays Harvard $20M For "Accelerated" Cancer Drugs [Xconomy]

5.4 Traitements - Economie

Do rebates really take a big chunk out of rising drug prices? Not necessarily, WaPo finds [FiercePharma]

NICE does a U-turn on J&J's Zytiga for pre-chemo after drugmaker offers cost-cutting deal [FiercePharma]

Disease-specific drug pricing could help tie cost to value [STAT]

Prostate cancer drug approved for routine use before chemotherapy [Cancer Research UK]

NHS urged to speed reforms after 3 year wait for prostate drug [The Telegraph]

6. Lutte contre les cancers

How close are we to curing cancer? [The Telegraph]

6.1 Observation

Well: No Regrets After Double Mastectomy, but Questions Remain [NY Times]

6.10 Politiques

France wants medicine prices to be on agenda at G7 summit: source [Reuters]

6.7 DMP, Big Data & applis

Are We Mining Data Instead Of Answering Questions? [Forbes]

6.7.2 Applis

23andMe to Share DNA Data with Researchers Using Apple iPhone [MIT Technology Review]

Mobile-phone health apps deliver data bounty [Nature News & Comment]

Apple Hopes You'll Talk to Your iPhone and Call Your Doctor in the Morning [MIT Technology Review]

6.9 Controverses

NEJM Responds to Allegations Its Correspondent Reported Confidential, Inaccurate Patient Information [Forbes]